nach oben

Erschienen in:

01.12.2014 | News item

Strengthened warnings for valproate use in females in EU

Erschienen in: Reactions Weekly | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Warnings will be strengthened on the use of valproate medicines in women and girls due to the risk of malformations and developmental problems in babies exposed to valproate in the womb, according to a decision made by the regulatory body representing EU Member States called the CMDh.¹ …

Coordination Group for Mutual Recognition and Decentralised Procedures - Human

see Reactions 1524 p4; 803109582

European Medicines Agency. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. Internet Document : [4 pages], 21 Nov 2014. Available from: URL: http://www.agenziafarmaco.gov.it/sites/default/files/Valproate%20-%20public%20health%20communication.pdf

Titel: Strengthened warnings for valproate use in females in EU
Publikationsdatum: 01.12.2014
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2014
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-014-5820-4

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Strengthened warnings for valproate use in females in EU

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Allopurinol

Fibrin

Benznidazole/nifurtimox

Carvedilol/ivabradine/ticagrelor interaction

Bevacizumab/fluorouracil/oxaliplatin

Fluorouracil